KMT2A and chronic myelomonocytic leukemia: In this study, we used optical genome mapping (OGM) to analyze the cytogenomic alterations in 1277 hematolymphoid neoplasms and identified KMT2A PTD exclusively in patients with myeloid neoplasms, including 35 (7%) with AML, 5 (2.2%) with MDS, and 5 (7.2%) with chronic myelomonocytic leukemia (CMML).